INVO Fertility earnings release, August 17, 2026

INVO Fertility, Inc. (IVF) · Form 8-K, Item 2.02 · Filed · SEC filing

Exhibit

99.1

INVO

Fertility Reports Second Quarter 2026 Results Highlighting Revenue Growth and Clinic Platform Profitability

Q2

2026 revenue increased 17% as INVO advances organic growth and a disciplined acquisition strategy focused on established, profitable fertility practices

Clinic platform was profitable on an Adjusted EBITDA basis before corporate operating and public company expenses

SARASOTA,

Fla., August 17, 2026 — INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and technologies, today announced financial results for the second quarter ended June 30, 2026.

Q2

2026 Financial Highlights (all metrics compared to Q2 2025 unless otherwise noted)

Recent

Highlights

Clinic-Level

Adjusted EBITDA

INVO

Fertility believes the clinic-level view provides investors with an important perspective on the earnings capacity and underlying value of its fertility services platform.

Management is focused on growing this contribution through higher patient volumes, expanded services and improved operating execution, while also adding (via its acquisition efforts) established, profitable clinics that can increase scale and allow corporate operating expenses to be supported across a larger revenue and earnings base.

Clinic-Level

Adjusted EBITDA

(Unaudited,

$ in thousands; before corporate operating expenses)

Clinic-Level

Adjusted EBITDA is a non-GAAP measure. See Use of Non-GAAP Measures. See full table reconciliation.

Management

Commentary

“The second quarter continued the progress we demonstrated in the first quarter and provided further validation of our strategy,” said

Steve Shum, Chief Executive Officer of INVO Fertility. “Revenue increased 17% supported by the first full-quarter contribution from Family Beginnings and continued growth initiatives across our clinic network. Just as importantly, the clinic platform remained profitable on an Adjusted EBITDA basis before corporate operating and public company expenses, generating approximately $333,000 during the second quarter and $0.95 million during fiscal 2025. We believe these results demonstrate both the underlying earnings power of the clinics we have assembled and the value of building a larger platform around them.”

“We also continued to execute on the next phase of our plan. In addition to realizing a full quarter of contribution from Family Beginnings, we brought the Birmingham clinic fully into the INVO organization and expanded the shared services and resources we provide across operations, finance, billing, human resources, and administration. Our objective is to pair strong local clinical teams with the support, capabilities, and best practices needed to grow patient volumes, broaden services, improve execution and make each clinic more successful as part of the INVO family.”

“Looking ahead, we intend to drive organic growth across our existing clinic network, leverage our corporate infrastructure across a larger revenue base, and pursue disciplined acquisitions of established, profitable fertility practices. With a growing operating platform, demonstrated clinic-level Adjusted EBITDA generation, an improved financial position, and a robust pipeline of opportunities, we believe INVO is increasingly well positioned to build a scaled fertility services company and create meaningful long-term value,” Shum concluded.

Second

Quarter Financial Discussion

Revenue for the second quarter of 2026 was approximately $2.2 million, compared to approximately $1.9 million for the second quarter of 2025.

The increase of approximately $0.3 million, or 17%, was primarily attributable to the addition of Family Beginnings following the February

2026 acquisition. Clinic revenue increased 18% to approximately $2.2 million, compared to approximately $1.8 million for the second quarter of 2025.

Cost of services was approximately $1.4 million for the second quarter of 2026, compared to approximately $1.1 million for the second quarter of 2025. The increase was primarily attributable to the addition of Family Beginnings and one-time staffing costs at the Georgia clinic.

Selling, general and administrative expenses decreased to approximately $1.9 million, compared to approximately $2.2 million for the second quarter of 2025, primarily reflecting lower professional services expenses.

The

Company reported a loss from operations of approximately $(1.3) million for the second quarter of 2026, compared to a loss from operations of approximately $(3.0) million for the second quarter of 2025. Net income was approximately $0.9 million, compared to a net loss of approximately $(3.6) million for the second quarter of 2025. The Company recognized an approximate gain of $2.5 million on remeasurement related to the Birmingham acquisition in the second quarter of 2026. The Company reported no loss from discontinued operations during the second quarter of 2026, compared to approximately $(2.1) million of losses from discontinued operations during the second quarter of 2025 related to NAYA Therapeutics.

The

Company ended the second quarter of 2026 with approximately $3.7 million in cash, compared to approximately $2.1 million at December 31, 2025.

Webcast

INVO

Fertility will host a webcast to discuss its Q2 2026 financial results and provide a business update on Monday, August 17, 2026, at 11:00 a.m. Eastern time.

Date and Time:

Monday, August 17, 2026, at 11:00 a.m. Eastern time.

Live

Webcast: https://app.webinar.net/yDAl3O9e8k4

Replay:

A webcast replay will be available at https://app.webinar.net/yDAl3O9e8k4.

Use of Non-GAAP Measure

Included... (truncated)s. These measures are not intended to be substitutes for financial measures reported in accordance with U.S. generally accepted accounting principles.

Management believes that, when considered together with the GAAP figures, these measures provide meaningful information regarding operating performance, the earnings contribution of the Company’s clinic platform and trends in the business.

Clinic-Level

Adjusted EBITDA represents Adjusted EBITDA generated by the Company’s fertility clinic operations before corporate operating expenses, as calculated by management. This measure is intended to provide visibility into the performance and earnings capacity of the operating clinic platform separately from the costs associated with managing a public company and building a larger acquisition platform. Adjusted

EBITDA and Clinic-Level Adjusted EBITDA may be calculated differently by INVO Fertility than by other companies that disclose measures with the same or similar terms.

About

INVO Fertility

We are a healthcare services fertility company dedicated to expanding access to assisted reproductive technology (“ART”) care to patients in need. Our principal commercial strategy is focused on building, acquiring, and operating fertility clinics and related businesses and technologies. Our acquisition strategy focuses on US-based, profitable fertility clinics. Our clinics offer a variety of fertility services including in vitro fertilization (“IVF”) and the intravaginal culture (“IVC”) procedure enabled by INVOcell. We have four operational fertility clinics in the United States. We also continue to engage in the sale and distribution of INVOcell to third-party owned and operated fertility clinics. INVOcell is a proprietary and revolutionary medical device, and the first to allow fertilization and early embryo development to take place in vivo within the woman’s body. For more information, please visit invofertility.com.

Safe

Harbor Statement

Financial statements

Income Statement

For the Three Months Ended June 30, — CONSOLIDATED STATEMENTS OF OPERATIONS

For the Three Months Ended June 30, – 2026For the Three Months Ended June 30, – 2025For the Six Months Ended June 30, – 2026For the Six Months Ended June 30, – 2025
Revenue:Clinic revenue2,167,7851,832,0944,150,0183,453,647
Revenue:Product revenue7,70031,56040,69247,192
Revenue:Total revenue2,175,4851,863,6544,190,7103,500,839
Operating expenses:Cost of services1,352,6651,090,5402,634,9122,131,485
Operating expenses:Cost of goods sold60,1473,06365,2997,047
Operating expenses:Selling, general, and administrative1,906,7502,193,0494,082,8493,750,371
Operating expenses:Impairment loss1,397,3531,397,353
Operating expenses:Depreciation and amortization145,573169,737288,271404,199
Operating expenses:Total operating expenses3,465,1354,853,7427,071,3317,690,455
Operating expenses:Loss from operations-1,289,650-2,990,088-2,880,621-4,189,616
Other income (expense):Gain (loss) from equity method investment-7,154-19,91115,014-4,815
Other income (expense):Gain on remeasurement2,452,0322,452,032
Other income (expense):Gain (loss) on change in fair value of warrant liability1,660,160-3,790,2251,660,160
Other income (expense):Loss on debt extinguishment-172,621-692,270-172,621-692,270
Other income (expense):Gain on settlement939,500939,500
Other income (expense):Interest income139,514139,514
Other income (expense):Interest expense-177,227-440,596-357,550-748,435
Other income (expense):Total other income (expense)2,234,5441,446,883-1,713,8361,154,140
Other income (expense):Net income (loss) from continuing operations before income taxes944,894-1,543,205-4,594,457-3,035,476
Other income (expense):Provision for income taxes56,15456,154
Other income (expense):Net income (loss) from continuing operations888,740-1,543,205-4,650,611-3,035,476
Other income (expense):Loss on disposition-1,534,517-1,534,517
Other income (expense):Loss from discontinued operations-541,247-16,452,562
Other income (expense):Net income (loss)888,740-3,618,969-4,650,611-21,022,555
Net income (loss) from continuing operations per common share:Basic0.42-155.31-2.48-405.93
Net income (loss) from continuing operations per common share:Diluted0.35-155.31-2.48-405.93
Net loss from discontinued operations per common share:Basic$--208.91$--2,405.38
Net loss from discontinued operations per common share:Diluted$--208.91$--2,405.38
Net income (loss) per common share:Basic0.42-364.23-2.48-2,811.31
Net income (loss) per common share:Diluted0.35-364.23-2.48-2,811.31
Weighted average number of common shares outstanding:Basic2,105,5959,9361,873,0197,478
Weighted average number of common shares outstanding:Diluted2,592,0259,9361,873,0197,478

Income Statement

CONSOLIDATED STATEMENTS OF OPERATIONS

For the Three Months Ended – June 30, – 2026For the Three Months Ended – June 30, – 2025
Adjusted EBITDANet income (loss) from continuing operations888,740-1,543,205
Adjusted EBITDAInterest expense177,227440,596
Adjusted EBITDAInterest income-139,514
Adjusted EBITDATax expense56,154
Adjusted EBITDADepreciation and amortization145,573169,737
Adjusted EBITDAStock-based compensation118,571680,680
Adjusted EBITDANon cash compensation for services45,000
Adjusted EBITDAGain on remeasurement-2,452,032
Adjusted EBITDAGain on change in fair value of warrant liability-1,660,160
Adjusted EBITDALoss from debt extinguishment172,621692,270
Adjusted EBITDAGain on settlement of liability-939,500
Adjusted EBITDAImpairment of intangible assets1,397,353
Adjusted EBITDANAYA divesture related costs130,000
Adjusted EBITDA-1,032,660-587,229

Income Statement

Fertility Clinic Services Segment — Clinic-Level Adjusted EBITDA

2025Q1 2026Q2 2026
Revenue6,721,0571,982,2332,167,785
Operating expenses7,753,3711,853,1091,867,454
Segment profit-1,032,314129,124300,331
Depreciation and amortization585,89734,82132,695
Impairment loss1,397,353
Fertility Clinic Services Segment EBITDA950,936163,945333,026
Full release

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section

21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform

Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements regarding organic growth initiatives, acquisition opportunities, integration of acquired clinics, balance sheet improvements, liquidity, the growth of our clinic platform and our ability to achieve cash flow break even or profitability, as well as statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,”

“expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties, and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events, or otherwise.

For more information, please contact:

INVO

Fertility, Inc.

Steve

Shum, CEO

978-878-9505 sshum@invofertility.com

Investor

Contact

Lytham

Partners, LLC

Robert

Blum

602-889-9700

INVO@lythampartners.com

INVO

FERTILITY, INC.

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · INVO Fertility earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.